BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$284.60 USD
+42.65 (17.63%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $285.16 +0.56 (0.20%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Bio-Rad Laboratories, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Products industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BIO 284.60 +42.65(17.63%)
Will BIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 10th
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Other News for BIO
Bio-Rad (BIO) Stock Surges Over 15%
UBS Increases Price Target for Bio-Rad (BIO) to $325
RBC Capital Raises Price Target for Bio-Rad Laboratories (BIO) to $409 | BIO Stock News
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
BIO Crosses Above Key Moving Average Level